医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Multimillion-Dollar Investment in the Atellica Solution will Transform Pathology Testing across Australia

2018年11月07日 PM10:30
このエントリーをはてなブックマークに追加


 

TARRYTOWN, N.Y.

Integrated healthcare provider Primary Health Care has joined forces with Siemens Healthineers to deploy more than 70 Atellica® Solution1 immunoassay and clinical chemistry analyzers. This marks Siemens Healthineers largest contract for in vitro diagnostics testing in Australia, and one of its most robust sales of the Atellica Solution. The analyzers are integrated with Atellica Diagnostics IT solutions and will connect to the company’s strategic partner Inpeco’s FlexLab track for total lab automation to deliver a high throughput multidisciplinary solution with capabilities that are transforming the clinical laboratory landscape across the country.

The strategic engagement couples Primary’s expansive network of more than 2,300 national pathology collection sites with workflow improvement and expanded clinical capabilities from Siemens Healthineers to establish a new level of automated diagnostic delivery. Through deep analytics, and intelligent data and process management, Atellica Diagnostics IT software will provide Primary with improved visibility, flexibility and control over its entire operation.

“This new collaboration will allow us to take Primary’s operational efficiencies to new heights,” said Wes Lawrence, Chief Executive of Pathology at Primary Health Care. “Thanks to this next-generation technology, we’re able to increase productivity, and focus more on value-adding lab activities and less on sample and instrument handling. In doing so, processes will be reduced and testing quality will be advanced, ultimately helping us increase cost savings and focus on the human impact of our work.”

Siemens Healthineers and Inpeco SA will deliver this fully automated multidisciplinary solution that will vastly simplify clinical and operational workflows and help Primary achieve better outcomes at much lower costs.

“Healthcare systems are constantly under pressure to drive efficiency, and to improve both clinical and business outcomes, said Deepak Nath, Ph.D., President, Laboratory Diagnostics Siemens Healthineers. “At Siemens Healthineers we’ve designed and built innovations that enable our customers to optimize processes and add value for laboratory staff and their healthcare facilities.”

Sebastian D’Angelo, General Manager, Laboratory Diagnostics, Australia, Siemens Healthineers added, “With the introduction of the Atellica Solution and the complementary, innovative offering of Atellica Diagnostics IT, we’ll turn what has been more than a decade of collaboration with Primary Health Care into an entirely new frontier for the Australian pathology industry.”

Primary Health Care has a large presence in all mainland states. One in every three pathology samples taken in Australia is tested in a Primary laboratory. The Siemens Healthineers technology will be rolled out in New South Wales, Queensland, Victoria and Western Australia. The scale of deployment through this opportunity will cement Siemens Healthineers as a market leader within the Australian pathology industry.

For more information about the Atellica Solution, visit https://www.healthcare.siemens.com/integrated-chemistry/systems/atellica-solution-analyzers

1 Product availability varies by country.

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.

In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005095/en/

CONTACT

For journalists
Siemens Healthineers
Kimberly Nissen,
+1-610-448-6355
Kimberly.Nissen@Siemens-Healthineers.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品、シャイアー買収提案に関する臨時株主総会通知案内状の発行を発表
  • China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
  • Celltrion Healthcare: Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems
  • 中国のNo.1ハイテク・フェアCHTF 2018のハイライト
  • Stanford Neuroscientist Karl Deisseroth Receives Japan’s Kyoto Prize in Advanced Technology